Ursula Hoffmann

USPTO Granted Patents = 11 (Patent Applications = 3)

CIPO Patents = 5 (Patent Applications = 2)

EPO Patents = 9 (Patent Applications = 7)

Average Co-Inventor Count = 3.0

ph-index = 5

Forward Citations = 54(Granted Patents)

Location History:

Basel, CH (2014 - 2020)
Muttenz, CH (2007 - 2024)

Company Filing History:

10 out of 4,942

Hoffmann-la Roche Inc.

Years Active: 2007-2024

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12084454 - Process for preparing BTK inhibitors (2024-09-10),

2. 10538536 - Process for the preparation of 2-pyrazolo[1,5-a]pyrazin-2-ylpyrido[1,2-a]pyrimidin-4-one compounds (2020-01-21),

3. 8895729 - Process for making thienopyrimidine compounds (2014-11-25),

4. 8765989 - Process (2014-07-01),

5. 8143442 - Preparation for a cyclohexanecarboxylic acid derivative and intermediates (2012-03-27),

6. 7977509 - Process for the preparation of acid halides (2011-07-12),

7. 7863474 - Process for the preparation of CETP(1) (2011-01-04),

8. 7858823 - Process for cyclohexanecarboxylic acid derivatives (2010-12-28),

9. 7728171 - Process for the production of acid chlorides (2010-06-01),

10. 7435849 - Process for the production of acid chlorides (2008-10-14),

11. 7259176 - Process for the preparation of the insulin sensitizer (2007-08-21),

Title: Ursula Hoffmann: Pioneering Inventor Shaping the Future of Innovation.

Introduction:

Ursula Hoffmann, a visionary inventor hailing from Muttenz, CH, is known for his remarkable passion for innovation and unwavering dedication to creating a better world through technology. With a repertoire of 10 patents under his belt, Hoffmann's contributions are poised to leave a lasting impact on the realm of inventors worldwide.

Latest Patents:

Among his latest groundbreaking patents is a process for the preparation of 2-pyrazolo[1,5-a]pyrazin-2-ylpyrido[1,2-a]pyrimidin-4-one compounds. This innovation showcases Hoffmann's expertise in developing pharmaceutically active compounds with immense therapeutic potential. Additionally, his process for making thienopyrimidine compounds, including the dual mTOR/PI3K inhibitor GDC-0980, signifies his profound impact on the pharmaceutical landscape.

Career Highlights:

Having worked at esteemed companies such as Hoffmann-La Roche Inc. and Genentech, Inc., Hoffmann has honed his craft alongside industry pioneers. His keen insights and innovative approach have led to the development of cutting-edge technologies that push the boundaries of what is possible in the field of medicine and beyond.

Collaborations:

Throughout his illustrious career, Hoffmann has collaborated with exceptional talents like Reinhard Reents and Helmut Werner Stahr. Together, they have embarked on transformative projects that have redefined the standard for innovation in their respective industries.

Conclusion:

In conclusion, Ursula Hoffmann emerges as a truly inspiring figure in the world of inventors, embodying the spirit of curiosity, perseverance, and ingenuity. His relentless pursuit of excellence and commitment to creating a positive impact underscore his importance in shaping the future of innovation for generations to come.

This text is generated by artificial intelligence and may not be accurate.